The Kirby Institute, UNSW Sydney, Sydney, Australia.
The Kirby Institute, UNSW Sydney, Sydney, Australia.
Int J Drug Policy. 2019 Oct;72:1-10. doi: 10.1016/j.drugpo.2019.07.016. Epub 2019 Jul 23.
There have been major strides towards the World Health Organization goal to eliminate hepatitis C virus (HCV) infection as a global public health threat. The availability of simple, well-tolerated direct-acting antiviral therapies for HCV infection that can achieve a cure in >95% of people has provided an important tool to help achieve the global elimination targets. Encouragingly, therapy is highly effective among people receiving opioid agonist therapy and people who have recently injected drugs. Moving forward, major challenges include ensuring that new infections are prevented from occurring and that people who are living with HCV are tested, linked to care, treated, receive appropriate follow-up, and have equitable access to care. This editorial highlights key themes and articles in a special issue focusing on the elimination of HCV among people who inject drugs. An overarching consideration flowing from this work is how to ensure equitable access to HCV treatment and care for all. This special issue maps the field in relation to: HCV prevention; the cascade of HCV care; strategies to enhance testing, linkage to care, and treatment uptake; and HCV treatment and reinfection. In addition, papers draw attention to the 'risk environments' and socio-ecological determinants of HCV acquisition, barriers to HCV care, the importance of messaging around the side-effects of new direct-acting antiviral therapies, the positive transformative potential of treatment and cure, and the key role of community-based drug user organizations in the HCV response. While this special issue highlights some successful efforts towards HCV elimination among people who inject drugs, it also highlights the relative lack of attention to settings in which resources enabling elimination are scarce, and where elimination hopes and potentials are less clear, such as in many low and middle income countries. Strengthening capacity in areas of the world where resources are more limited will be a critical step towards ensuring equity for all so that global HCV elimination among PWID can be achieved.
在实现世界卫生组织消除丙型肝炎病毒(HCV)感染这一全球公共卫生威胁的目标方面已经取得了重大进展。目前,针对 HCV 感染的简单、耐受性良好的直接作用抗病毒疗法可使 95%以上的患者实现治愈,这为实现全球消除目标提供了重要工具。令人鼓舞的是,这些疗法在接受阿片类药物激动剂治疗和最近注射毒品的人群中非常有效。未来,主要挑战包括确保新的感染得到预防,以及让 HCV 感染者接受检测、接受治疗、获得适当的后续治疗并获得公平的治疗机会。本社论重点介绍了一个特刊中关于在注射毒品者中消除 HCV 的重点主题和文章。这项工作的一个首要考虑因素是如何确保所有 HCV 感染者都能公平获得治疗和护理。该特刊在以下方面描绘了该领域的情况:HCV 预防;HCV 护理的各个环节;增强检测、护理衔接和治疗参与的策略;HCV 治疗和再感染。此外,论文还提请注意 HCV 获得的“风险环境”和社会生态决定因素、HCV 护理的障碍、新的直接作用抗病毒疗法副作用信息的重要性、治疗和治愈的积极变革潜力,以及社区为基础的吸毒者组织在 HCV 应对中的关键作用。虽然本特刊强调了在注射毒品者中消除 HCV 的一些成功努力,但也强调了在资源有限的情况下,对消除资源匮乏的环境关注相对较少,在这些环境中,消除的希望和潜力不太明确,如在许多低收入和中等收入国家。加强资源有限地区的能力将是确保所有人都能获得公平待遇的关键步骤,从而实现注射毒品者的全球 HCV 消除目标。